A hospital-based study: Risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy

Clinical Neurology and Neurosurgery

Volumn 108, Issue 8, 2006, Pages 726-732

  Benbir, Gülçin ^a   Özekmekçi, Sibel ^a   Apaydin, Hülya ^a   Delil, Sakir ^a   Erginöz, Ethem ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Dyskinesia; Levodopa; Motor complications; Parkinson's disease; Wearing off phenomenon

Indexed keywords

BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; LISURIDE; PERGOLIDE; PIRIBEDIL; SELEGILINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DYSKINESIA; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; ONSET AGE; PARKINSON DISEASE; RATING SCALE; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; LEVODOPA; LONG-TERM CARE; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; PATIENT ADMISSION; RETROSPECTIVE STUDIES; RISK FACTORS; TURKEY;

EID: 33750713345     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2006.02.002     Document Type: Article

References (47)

1. Marsden C.D., and Parkes J.D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1 (1976) 292-296
2. Obeso J.A., Rodriguez-Oroz M.C., Chana P., Lera G., Rodriguez M., and Olanow C.W. The evolution and origin of motor complications in Parkinson's disease. Neurology 4 (2000) S13-S20
3. Koller W.C., and Hubble J.P. Levodopa therapy in Parkinson's disease. Neurology 40 (1990) 40-47
4. Obeso J.A., Olanow W., and Nutt J.G. Levodopa motor complications in Parkinson's disease. Trends Neurosci 23 (2000) S2-S7
5. Olanow C.W., Watts R.L., and Koller W.C. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology 56 Suppl 5 (2001) S1-S88
6. Jankovic J. Complications and limitations of drug therapy for movement disorders. Neurology 55 (2000) S2-S6
7. Rascol O. l-Dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach. Mov Disord 14 (1999) 19-32
8. Riley D.E., and Lang A.E. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 43 (1993) 1459-1464
9. Marras C., Lang A., Krahn M., Tomlinson G., and Naglie G. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. Mov Disord 19 (2004) 22-28
10. Vidailhet M., Bonnet A.M., and Marconi N. The phenomenology of l-Dopa-induced dyskinesias in Parkinson's disease. Mov Disord 14 (1999) 13-18
11. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 47 (2000) S2-S11
12. Jankovic J. Levodopa strengths and weaknesses. Neurology 58 (2002) S19-S32
13. Thobois S., Delamarre-Damier F., and Derkinderen P. Treatment of motor dysfunction in Parkinson's disease: an overview. Clin Neurol Neurosurg 107 (2005) 269-281
14. Golbe L.I. Young-onset Parkinson's disease: a clinical review. Neurology 41 (1992) 168-173
15. Quinn N., Critchley P., and Marsden C.D. Young-onset Parkinson's disease. Mov Disord 2 (1987) 73-91
16. Schrag A., and Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease: a community-based study. Brain 123 (2000) 2297-2305
17. Jankovic J. Parkinson's disease therapy: tailoring choices for early and late disease, young and old patients. Clin Neuropharmacol 23 (2000) 252-261
18. Schrag A., Hovris A., Morley D., Quinn N., and Jahanshahi M. Young- versus older-onset Parkinson's disease: impact of disease and psychosocial consequences. Mov Disord 18 (2003) 1250-1256
19. Schrag A., Ben-Shlomo Y., Brown R., Marsden C.D., and Quinn N. Young-onset Parkinson's disease revisited: clinical features, natural history, and mortality. Mov Disord 13 (1998) 885-894
20. Fahn S. Parkinson's disease, the effect of levodopa, and the ELLDOPA trial. Arch Neurol 56 (1999) 529-535
21. Fahn S. Results of the ELLDOPA (earlier vs. later levodopa) study. Mov Disord 17 (2002) S13
22. Marsden C.D., and Parkes J.D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1 (1977) 345-349
23. Poewe W.H., Lees A.J., and Stern G.M. Low-dose l-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 36 (1986) 1528-1530
24. Hughes A.J., Ben-Shlomo Y., and Lees A.J. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 42 (1992) 1142-1146
25. Hoehn M.M., and Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 17 (1967) 427-442
26. Fahn S., Elton R.S., and Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S., Marsden C.D., Calne D.B., and Goldstein M. (Eds). Recent developments in Parkinson's disease (1987), Macmillan, Florham Park, NJ 153-163
27. Miyawaki E., Lyons K., Pahwa R., Troster A.I., Hubble J., Smith D., et al. Motor complications of chronic levodopa therapy in Parkinson's disease. Clin Neuropharmacol 20 (1997) 523-530
28. Lang A.E., and Lozano A.M. Parkinson's disease. N Engl J Med 339 (1998) 1044-1053
29. Hely M.A., Morris J.G.L., Reid W.G., O'Sullivan D.J., Williamson P.M., Rail D., et al. The Sydney Multicentre Study of Parkinson's Disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 57 (1994) 903-910
30. Fahn S. Adverse effects of levodopa. In: Olanow C.W., and Lieberman A.N. (Eds). The Scientific Basis for the Treatment of Parkinson's Disease (1992), Parthenon Publishing Group, Lancs, UK 89-112
31. Montastruc J.L., Rascol O., Senard J.M., and Rascol A. A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five-year follow-up. J Neurol Neurosurg Psychiatry 57 (1994) 1034-1038
32. Baba Y., Putzke J.D., Whaley N.R., Wszolek Z.K., and Uitti R.J. Gender and the Parkinson's disease phenotype. J Neurol 252 10 (2005) 1201-1205
33. Ahlskog J.E., and Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from cumulative literature. Mov Disord 16 (2001) 448-458
34. Block G., Liss C., Reines S., Irr J., and Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. Eur Neurol 37 (1997) 23-27
35. Koller W.C., Hutton J.T., Tolosa E., and Capilldeo R. Immediate-release and controlled release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Neurology 53 (1999) 1012-1019
36. Rajput A.H., Fenton M.A., Birdi S., Macaulay R., George D., Rozdilsky B., et al. Clinical-pathological study of levodopa complications. Mov Disord 17 (2002) 289-296
37. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 39 (1996) 37-45
38. Nutt J.G., Carter J.H., Van Houten L., and Woodward W.R. Short- and long-duration responses to levodopa during the first year of levodopa therapy. Ann Neurol 42 (1997) 349-355
39. Chikina E., and Gusev E. The initial dose of levodopa influences on occurrence motor complications of Parkinson's disease. Parkinsonism Relat Disord 11 (2005) 132
40. Pepe A., Dambrosia J.M., and Chase T.N. Risk factors for motor response complications in l-dopa-treated parkinsonian patients. Adv Neurol 60 (1993) 698-702
41. Bracco F., Battaglia A., Chouza C., and PKDS009 Study Group. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 18 (2004) 733-746
42. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287 (2002) 1653-1661
43. Chase T.N., Engber T.M., and Mouradian M.M. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology 44 (1994) S15-S18
44. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., and Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342 (2000) 1484-1491
45. Whone A., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54 (2003) 93-101
46. Poewe W.H. Clinical aspects of motor fluctuations in Parkinson's disease. Neurology 44 (1994) S6-S9
47. Grimes J.D., King D.B., Kofman O.S., Molina-Negro P., Wilson A.F., and Bouchard S. Bromocriptine in the management of "end-of-dose" deterioration in Parkinson's disease. Can J Neurol Sci 11 (1984) 452-456